Starting Your Clinical Journey with the End in Mind – the Value of a Drug Development Plan
Establishing an intelligent clinical development program pathway from the start is vital for clarity around the complex processes required to achieve product registration.
The Drug Development Plan (DDP) plan informs every part of the journey from budgeting, capital-raising, timelines, clinical phases, research partners, research locations, regulator engagement, staff hires and much more.
Ultimately a DDP describes the steps that are required to generate the evidence to support marketing authorisation and reimbursement.
An external DDP advising team needs to be expert across all regulatory affairs and product development including manufacturing, toxicology and medical writing, and planning should start from the pre-clinical development phase.
The planning process cuts risks including unexpected regulatory hurdles and cost, and ensures the drug’s progress aligns with investor expectations, as well as optimising resources throughout the clinical program.
It also covers CMC quality requirements, non-clinical requirements, the non-clinical animal studies required, and the type and scope of clinical studies to support the product registration.
In addition to the typical Phase I, II and III program, the DDP can highlight any extra requirements, or studies that might be needed to support the application, such as clinical studies in special populations, or drug interaction studies.
One of the most important processes is a commercial or competitor analysis of products on the market, or currently in development. This informs the kind of studies and information that will be needed to support the marketing authorisation of the product.
A robust DPP also identifies ways to accelerate drug approval. There are a range of processes that regulators offer in order to speed up drug development and approvals. They include orphan drug designation for a rare indications, and for truly exciting products that are impacting life-threatening disease there are options including breakthrough therapy and fast track designation programs.
DDP key points include:
Starting off with a scientific rationale for the development of the product, which includes a brief summary of the target indication, and why the product is being developed. This sets the scene for the product development.
An analysis of similar competitor products that are on the market or are currently in development. This is an important part of commercial analysis, but also provides useful information on the kinds of studies and information that will be needed to support the marketing authorisation of the product.
The product targeting could be for global registration or a single region such as the Asia-Pacific with others such as the US and Europe to be added later in the development program.
An assessment of the manufacturing quality requirements at the different stages of development. Starting off with Phase I GMP, and then moving through to process validation for marketing authorisation.
The clinical trial strategy comprising Phase I, Phase II, Phase III, may expand if say other populations need to be considered, or there may be an opportunity for a compressed clinical development strategy.
Commercial importance requires timelines and costs, or at least estimates, so a company knows how much to raise or how long it is going to take.
Then finally, include key decision points in the development plan where you decide whether or not it is worthwhile to continue the development of that program.